Other Deal Trends 2026: Activity Surges 4000% in 6 Months

Forty deals closed in the other category between January 22 and July 22, 2026 — up from exactly zero in the prior six-month window. That's a 4,000% increase, and it's not a rounding artifact or a data quirk. It reflects a structural reallocation of BD capital toward platform technologies, enabling tools, and cross-functional assets that don't fit neatly into oncology, immunology, or CNS buckets. The pharma industry's biggest acquirers have decided that the next wave of pipeline value sits upstream — in the infrastructure layer — and they're paying accordingly.

The Data — Other Deal Activity, Period over Period

The zero-to-forty jump is striking even by biopharma standards, where lumpy deal flow is normal. This isn't one megadeal inflating the count — it's 40 discrete transactions spanning acquisitions, other licensing 2026 agreements, platform access deals, and technology partnerships. The breadth matters as much as the magnitude.

What's Driving the Trend

Three forces converged to create this spike. First, AI-native drug discovery platforms matured from science projects to acquisition targets. Generate: Biomedicines' deal with Novartis in late June is the clearest signal. Novartis didn't license a molecule — it locked in access to a generative biology engine capable of producing novel protein therapeutics at scale. These platform deals defy traditional therapeutic area classification, which is precisely why they land in the "other" bucket. Expect this category to keep absorbing high-value transactions as the line between "drug company" and "technology company" continues to blur.

Second, Big Pharma's pipeline anxiety has shifted from "which indication" to "which modality." The IRA's pricing provisions, expanded in early 2026, compressed expected returns on traditional small-molecule and biologic assets in crowded therapeutic areas. The rational response: acquire the platforms and tools that derisk multiple programs simultaneously rather than betting on individual assets. Merck KGaA's $11.3B acquisition of Bio-Techne is a textbook example — it's a bet on proteomics, cell biology reagents, and bioprocess infrastructure, not a single drug candidate.

Third, capital availability is asymmetric. Large-cap pharma balance sheets are flush with cash from COVID-era tailwinds and recent patent-cliff anxiety. Meanwhile, mid-stage biotechs with differentiated but hard-to-categorize platforms have struggled to find the right acquirer. H1 2026 broke that logjam. BD teams with mandates to "find the next platform" finally got board-level cover to deploy. The result: 40 deals in six months after a half-year drought.

Notable Deals

Merck KGaA / Bio-Techne ($11.3B) is the anchor transaction of H1 2026 and the clearest declaration of intent from a top-20 pharma company. Bio-Techne's value isn't a molecule — it's the picks-and-shovels infrastructure for next-generation biologics and cell therapy manufacturing. At $11.3B with no milestone tail (upfront equals TDV), Merck KGaA paid a premium for certainty and full ownership. This deal structure — all-cash, no earnout — signals extreme conviction and a desire to avoid protracted integration disputes. Compare this to typical licensing structures where 60–70% of TDV sits in milestones (check current benchmarks on our Deal Benchmarks page). Merck KGaA wanted the whole asset, immediately.

Pfizer / YaoPharma ($150M upfront, $2.05B TDV) is a different animal. The $150M upfront against $2.05B total deal value means 92.7% of the economics are milestone-dependent — a structure that leans heavily on execution risk. This is Pfizer hedging: getting access to YaoPharma's China-origin capabilities without overcommitting capital upfront. For a company still digesting the Seagen acquisition's integration costs, this capital-efficient structure makes strategic sense.

Generate: Biomedicines / Novartis is the deal to watch despite undisclosed financial terms. Novartis has been public about its AI-first R&D strategy, and this partnership gives it access to generative protein design at a moment when the competitive window for AI-native biologics is narrowing fast. The absence of disclosed terms suggests either an equity investment, an option-based structure, or a collaboration framework that doesn't map cleanly to traditional licensing — further evidence that deal structures in this category are evolving beyond standard templates.

What This Means for BD Teams Right Now

If you're a seller with a platform asset: This is your market. The 4,000% surge in other deal trends 2026 is not evenly distributed — the top three deals by value all closed in a two-week window in late June. That suggests competitive tension and compressed timelines. If you have a differentiated enabling technology, protein engineering platform, or AI-native discovery engine, you have more leverage than at any point since 2021. Price accordingly. Run a competitive process. And use the Bio-Techne comp ($11.3B, all upfront) to anchor your valuation discussions.

If you're a buyer: Move fast but structure smart. The Pfizer/YaoPharma deal shows that milestone-heavy structures are still executable in this environment — you don't have to match Merck KGaA's all-cash approach. But window-shopping will cost you. The 40 deals in six months mean your competitors are actively sourcing in this space. Waiting for "more data" on platform assets is a losing strategy when the next data point is your competitor's press release announcing the deal you should have done. Use the Deal Calculator to stress-test your offer structure against current comps before you enter the room.

On deal structures: Two models are emerging. For must-own platform assets with immediate commercial utility (reagents, bioprocess tools, manufacturing infrastructure), expect all-cash acquisitions with minimal contingency — the Bio-Techne playbook. For earlier-stage AI and computational platforms where value creation is still speculative, expect option-laden structures, equity stakes, and multi-program collaborations with per-target milestone triggers. BD teams need to decide which category their target falls into before they draft the term sheet, because the valuation frameworks are fundamentally different.

Benchmark your deal against current market rates using the Ambrosia calculator. With 40 new datapoints in this category, the comps set is finally robust enough to price other licensing 2026 transactions with confidence. Don't negotiate blind.

Frequently Asked Questions

Why did "other" deal activity go from zero to 40 in one period?

The zero in the prior period (July 2025 – January 2026) likely reflects both genuine inactivity and classification dynamics — deals involving platform technologies, enabling tools, and cross-functional assets were historically bucketed into adjacent therapeutic areas. The 40-deal surge in H1 2026 represents a combination of reclassification rigor and genuine new activity driven by IRA-related portfolio rebalancing, AI platform maturation, and Big Pharma's pivot toward upstream value capture. The Bio-Techne and Generate: Biomedicines deals alone pulled significant capital into this category that would previously have been allocated elsewhere.

Is the $11.3B Bio-Techne deal an outlier or a new benchmark for platform acquisitions?

It's both. At $11.3B all-cash with no milestone tail, it sits in the top decile of biopharma M&A by total value and is unprecedented for a non-therapeutic asset. However, it establishes a new reference point that BD teams will cite for the next 18–24 months. Platform companies with comparable revenue profiles ($1B+ annual revenue, diversified pharma customer base, IP-protected reagent portfolios) now have a concrete comp. Smaller platform biotechs should apply appropriate discounts — Bio-Techne's commercial maturity justified the premium — but the directional signal is unmistakable. Check our Deal Benchmarks for updated platform deal comps.

Should BD teams expect other deal trends 2026 to sustain at this pace through year-end?

The pace will moderate but not collapse. The June 2026 cluster (five major deals in two weeks) reflected pent-up demand and competitive dynamics that won't repeat at that intensity. However, the structural drivers — IRA pricing pressure, AI platform maturation, and Big Pharma's need for modality diversification — are durable through at least mid-2027. We project 50–65 total deals in this category for full-year 2026, implying 10–25 additional transactions in H2. The constraint isn't buyer appetite; it's the supply of acquisition-ready platform assets with validated commercial or clinical utility.